Skip to main content
Premium Trial:

Request an Annual Quote

Oncocyte to Raise $35M in Public Stock Offering

NEW YORK – Oncocyte on Friday priced a public offering of 7,780,000 shares of its common stock at $4.50 per share.

The Irvine, California-based firm expects gross proceeds from the offering to be about $35 million. It also is granting underwriters a 30-day option to purchase up to an additional 1,167,000 shares of its common stock at the same price.

Piper Sandler is acting as the sole book-runner for the offering, which is expected to close on or about Feb. 9. BTIG and Needham are acting as co-lead managers.

Oncocyte said it intends to use net proceeds from the offering to promote commercialization of its lead diagnostic test, DetermaRx, and to complete development of its cancer immunotherapy predictor DetermaIO. The funds will also support development of future tests in its pipeline, including the CNI Monitor liquid biopsy assay that the firm is slated to acquire through its planned merger with Chronix Biomedical.

Proceeds may also be used for post-acquisition obligations related to the Chronix deal, for purchases related to Oncocyte's earlier acquisitions of Razor Genomics and Insight Genetics, and to invest in or acquire new businesses or technologies, although there are no binding agreements to acquire such business or technology at this time.

In early morning trade on the Nasdaq, shares of Oncocyte were up around 7 percent at $5.66.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.